Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease

Inclusion Criteria:

• Men or women greater than or equal to 18 years of age
• The subject has voluntarily signed and dated the most recent informed consent form approved by an Institutional Review Board
• Screening estimated glomerular filtration rate (eGRF) greater than or equal to 30 and less than or equal to 45 mL/min/1.72m2 plus or minus 10% for subjects with CKD and greater than 60mL/min for subjects acting as normal healthy controls
• Willing and able to cooperate with all aspects of the study protocol
• No evidence of significant gastrointestinal (GI) disorder that would impair GI motility or function
• No recent active illness or hospitalization within 12 weeks prior to the Day 1/Baseline visit
• No recent or voluntary change in diet within 4 weeks prior to Day 1/ Baseline visit
• No history of intolerance or adverse effects to lanthanum carbonate
• No use of calcium supplements for at least 2 weeks prior to Day 1
• Must have no dietary restrictions or significant allergies and be willing to eat a non-vegan standardized meal
• Subjects taking nutritional vitamin D or any active vitamin D must be on stable doses with no change during the 4 week period prior to Day 1

Exclusion Criteria:

• Current history of drug or alcohol abuse as assessed by the Principal Investigator
• Receiving active chemotherapy treatment for a malignancy
• Has received dialysis or has acute kidney injury within 12 weeks prior to screening or during screening
• Subject has a clinical condition that in the judgement of the Principal Investigator could potentially pose a health risk to the patient while involved int he study
• Received or has received an investigational product (or is currently using an investigational device) within 30 days prior to screening
• Evidence of active (clinically significant) infections within 14 days prior to Day1/ Baseline visit (in the opinion of the investigator)
• Use of phosphate binding medications (calcium carbonate or acetate with meals, lanthanum carbonate, or sevelamer carbonate)within 7 days prior to the Day 1/ Baseline visit
• Significant GI co-morbidity that would preclude use of lanthanum carbonate phosphate binder (e.g. colostomy with unformed stool, uncontrolled diarrhea)